(Q40478116)

20 September 2017

1 reference

title

Infections during low-dose methotrexate treatment in rheumatoid arthritis. (English)

1 reference

20 September 2017

1 reference

Boerbooms AM

1

1 reference

20 September 2017

Kerstens PJ

2

1 reference

20 September 2017

van Loenhout JW

3

1 reference

20 September 2017

Mulder J

4

1 reference

20 September 2017

van de Putte LB

5

1 reference

20 September 2017

publication date

1 June 1995

1 reference

Seminars in Arthritis and Rheumatism

20 September 2017

published in

1 reference

20 September 2017

volume

24

1 reference

20 September 2017

issue

6

1 reference

20 September 2017

page(s)

411-421

1 reference

Methotrexate in the treatment of rheumatoid arthritis; pilot study

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980009-3

7 January 2021

Low dose oral methotrexate in rheumatoid arthritis: an uncontrolled trial and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980009-3

7 January 2021

Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980009-3

7 January 2021

Low-dose methotrexate treatment of rheumatoid arthritis. Long-term observations

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980009-3

7 January 2021

Efficacy of low-dose methotrexate in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980009-3

7 January 2021

Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double-blind study.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980009-3

7 January 2021

Methotrexate and rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980009-3

7 January 2021

Low-dose methotrexate compared with azathioprine in the treatment of rheumatoid arthritis. A twenty-four-week controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980009-3

7 January 2021

The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980009-3

7 January 2021

A long-term prospective study of the use of methotrexate in rheumatoid arthritis. Update after a mean of fifty-three months

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980009-3

7 January 2021

Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980009-3

7 January 2021

Methotrexate in refractory rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980009-3

7 January 2021

Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980009-3

7 January 2021

Prospective long term follow-up of methotrexate therapy in rheumatoid arthritis: toxicity, efficacy and radiological progression

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980009-3

7 January 2021

Comparative controlled trial of low-dose weekly methotrexate versus azathioprine in rheumatoid arthritis: 3-year prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980009-3

7 January 2021

Low-dose methotrexate compared with auranofin in adult rheumatoid arthritis. A thirty-six-week, double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980009-3

7 January 2021

Long-term methotrexate therapy for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980009-3

7 January 2021

Methotrexate versus azathioprine in the treatment of rheumatoid arthritis. A forty-eight–week randomized, double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980009-3

7 January 2021

Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980009-3

7 January 2021

Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980009-3

7 January 2021

Comparison of azathioprine, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980009-3

7 January 2021

Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980009-3

7 January 2021

Low-dose methotrexate in rheumatic diseases--efficacy, side effects, and risk factors for side effects

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980009-3

7 January 2021

Methotrexate maintenance therapy and liver damage in psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980009-3

7 January 2021

Pneumocystis carinii pneumonia following methotrexate therapy for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980009-3

7 January 2021

Cryptococcosis associated with low-dose methotrexate for arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980009-3

7 January 2021

Herpes zoster in patients with rheumatoid arthritis treated with weekly, low-dose methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980009-3

7 January 2021

Rheumatoid arthritis, methotrexate therapy, and Pneumocystis pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980009-3

7 January 2021

Pneumocystis carinii pneumonia complicating low dose methotrexate treatment for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980009-3

7 January 2021

Cytomegalovirus pneumonia in a patient with rheumatoid arthritis treated with low dose methotrexate and prednisone

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980009-3

7 January 2021

PNEUMOCYSTIS CARINII INFECTION COMPLICATING CYTOTOXIC THERAPY IN TWO PATIENTS WITH LYMPHOPENIA, BUT A NORMAL TOTAL WHITE CELL COUNT

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980009-3

7 January 2021

Pneumocystis carinii pneumonia associated with low dose methotrexate treatment for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980009-3

7 January 2021

Local infectious complications following large joint replacement in rheumatoid arthritis patients treated with methotrexate versus those not treated with methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980009-3

7 January 2021

Urinary tract infection in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980009-3

7 January 2021

Psoriasis, methotrexate and tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980009-3

7 January 2021

Pneumocystis carinii pneumonia complicating low dose methotrexate treatment for psoriatic arthropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980009-3

7 January 2021

Mechanisms of Glucocorticoid Action on Immune Processes

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980009-3

7 January 2021

Risk of infectious complications in patients taking glucocorticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980009-3

7 January 2021

The efficacy and safety of low-dose corticosteroids for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980009-3

7 January 2021

Frequency of infections among rheumatoid arthritis patients, before and after disease onset

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980009-3

7 January 2021

Frequency of infection among patients with rheumatoid arthritis versus patients with osteoarthritis or soft tissue rheumatism

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980009-3

7 January 2021

Infection in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980009-3

7 January 2021

Rheumatoid arthritis and mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980009-3

7 January 2021

Cause and age at death in a prospective study of 100 patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980009-3

7 January 2021

Response of immunoregulatory lymphocyte subsets to methotrexate in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980009-3

7 January 2021

Methotrexate: mechanism of action in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980009-3

7 January 2021

Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor alpha, and interleukin-6 levels in rheumatoid arthritis. Longitudinal evaluation during methotrexate and azathioprine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980009-3

7 January 2021

Inhibition of neutrophil chemotaxis in methotrexate-treated rheumatoid arthritis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980009-3

7 January 2021

A Controlled Trial of Cyclophosphamide in Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980009-3

7 January 2021

Controlled trial of cyclophosphamide in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980009-3

7 January 2021

Infectious complications of cyclophosphamide treatment for vasculitis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980009-3

7 January 2021

The effects of methotrexate on the production and activity of interleukin-1

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2895%2980009-3

7 January 2021

10.1016/S0049-0172(95)80009-3

Identifiers

DOI

1 reference

20 September 2017

1 reference